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ABSTRACT
Objective: In patients with diabetes mellitus,
metformin treatment is associated with reduced
mortality and attenuation of cardiovascular risk. As a
subanalysis of the Glycometabolic Intervention as
adjunct to Primary Coronary Intervention in ST
Elevation Myocardial Infarction (GIPS-III) study, we
evaluated whether metformin treatment in patients with
ST-segment elevation myocardial infarction (STEMI)
without diabetes improves the cardiovascular risk
profile.
Methods: A total of 379 patients, without known
diabetes, presenting with STEMI were randomly
allocated to receive metformin 500 mg twice daily or
placebo for 4 months.
Results: After 4 months, the cardiovascular risk
profile of patients receiving metformin (n=172) was
improved compared with placebo (n=174); glycated
hemoglobin (5.83% (95% CI 5.79% to 5.87%) vs
5.89% (95% CI 5.85% to 5.92%); 40.2 mmol/mol
(95% CI 39.8 to 40.6) vs 40.9 mmol/mol (40.4 to
41.2), p=0.049); total cholesterol (3.85 mmol/L (95%
CI 3.73 to 3.97) vs 4.02 mmol/L (95% CI 3.90 to
4.14), p=0.045); low-density lipoprotein cholesterol
(2.10 mmol/L (95% CI 1.99 to 2.20) vs 2.3 mmol/L
(95% CI 2.20 to 2.40), p=0.007); body weight
(83.8 kg (95% CI 83.0 to 84.7) vs 85.2 kg (95% CI
84.4 to 86.1), p=0.024); body mass index (26.8 kg/m2
(95% CI 26.5 to 27.0) vs 27.2 kg/m2 (95% CI 27.0 to
27.5), p=0.014). Levels of fasting glucose,
postchallenge glucose, insulin, high-density
lipoprotein cholesterol, and blood pressure were
similar in both groups.
Conclusions: Among patients with STEMI without
diabetes, treatment with metformin for 4 months
resulted in a modest improvement of the
cardiovascular risk profile compared with placebo.
Trial register number: NCT01217307.
INTRODUCTION
After ST-segment elevation myocardial infarc-
tion (STEMI), secondary prevention therap-
ies as recommended by current guidelines
such as β-blockers, ACE inhibitors, platelet
aggregation inhibitors (acetylsalicylic acid
and others), and lipid-lowering drugs all
have been proven to reduce mortality and
attenuate cardiovascular risk proﬁle.1 In add-
ition to the targeted substrates by current
therapies, such as blood pressure, neuroen-
docrine activation, and increased thrombo-
genicity, glycometabolic dysregulation is
strongly associated with adverse outcome
after STEMI.2 Impaired fasting glucose and
insulin resistance is associated with impaired
prognosis, even at levels of dysglycemia not
yet diagnostic of diabetes mellitus.3–5
Dysglycemia is common in patients with
STEMI—as much as one in every four
patients have undiagnosed diabetes and up
Key messages
▪ In patients with acute myocardial infarction at
risk for diabetes, 4 months of treatment with
metformin on top of optimal treatment resulted
in a modestly more favorable cardiovascular risk
profile compared with placebo.
▪ Perhaps the most important and clinically the
most relevant observation was the reduction in
weight gain associated with metformin use.
Weight loss may be the key factor responsible
for metformin’s alleged cardioprotective effects.
▪ Metformin resulted in an improvement of choles-
terol levels on top of optimal statin therapy.











pen Diab Res Care: first published as 10.1136/bmjdrc-2015-000090 on 11 December 2015. Downloaded from 
to one in every two patients has prediabetes.6 Although
glycometabolic dysregulation is both common and
strongly associated with adverse outcomes after STEMI,
it nonetheless is not a target of current
pharmacotherapy.
Metformin is an effective glucose-lowering biguanide
and currently the most widely used oral antihyperglyce-
mic agent.7 Metformin has been shown to improve car-
diovascular outcome, with a beneﬁt that exceeds the
beneﬁt that may be expected solely by blood glucose
lowering.8–18 In patients with diabetes mellitus and car-
diovascular disease, metformin was associated with
reduced all-cause mortality compared with other antihy-
perglycemic strategies.8–11 Long-term metformin treat-
ment in patients at risk for or with diabetes improved
cardiovascular risk proﬁle mediated by weight loss,
improved insulin resistance, reduction of the metabolic
syndrome, and by lowering total and low-density lipopro-
tein (LDL) cholesterol.13–21 Further, in patients at risk
for diabetes, but without cardiovascular disease, metfor-
min reduced diabetes development with 30–40%.13–16
We aimed to evaluate if metformin treatment, on top
of standard care, would improve cardiovascular risk in
patients without diabetes. We therefore conducted this
prespeciﬁed subanalysis in the ‘Metabolic Modulation
With Metformin to Reduce Heart Failure After Acute
Myocardial Infarction: Glycometabolic Intervention as
adjunct to Primary Coronary Intervention in ST
Elevation Myocardial Infarction (GIPS-III)’ study, that
enrolled patients without diabetes who underwent
primary percutaneous coronary intervention (PCI) for
STEMI.
METHODS
The study design and baseline characteristics of the
single-center, randomized, double-blind, placebo-
controlled GIPS-III trial have been reported previ-
ously.22 23 In brief, patients presenting at the University
Medical Center Groningen between January 1, 2011 and
May 26, 2013 who underwent acute catheterization for
suspicion of STEMI were considered for this trial.
Patients older than 18 years who underwent a successful
primary PCI with implantation of at least one stent were
eligible. Exclusion criteria were known diabetes (deﬁned
as documented history of diabetes, current use of antihy-
perglycemic medication or verbal conﬁrmation by the
patient, or glycated hemoglobin (HbA1c) of ≥6.5%
(48 mmol/mol) prior to admission),24 previous myocar-
dial infarction, severe renal dysfunction, need for coron-
ary artery bypass grafting, conditions resulting in
inability to provide informed consent, and conditions
that interfered with the ability to comply with the
protocol.
The study protocol was in accordance with the
Declaration of Helsinki (Fortaleza, 2013), Dutch laws,
and was approved by the local ethics committee
(Groningen, the Netherlands) and national regulatory
authorities. The study received ﬁnancial support from
the Netherlands Organization for Medical Research
(ZonMw; grant nr. 95103007); the funding source had
no role in the study.
Procedures
The study procedures and main outcomes have been
described in detail.22 23 In short, immediately after cor-
onary angiography and subsequent coronary interven-
tion, 379 patients were randomly allocated to metformin
500 mg or visually matching placebo, both administered
twice daily. Patients provided verbal informed consent
during the PCI procedure and the ﬁrst dose was admi-
nistered immediately after arrival at the coronary care
unit (CCU).
At admission, body weight, height, blood pressure,
and heart rate were measured, and body mass index
(BMI) was calculated. Blood was drawn during primary
PCI, and blood glucose, HbA1c, insulin, creatinine, and
cholesterol levels were assessed. A detailed history
including cardiovascular risk proﬁle was assessed during
hospitalization. Patients arriving at the CCU between
00:00 and 20:59 were subjected to a standardized oral
glucose tolerance test (OGTT) with 75 g of glucose (dis-
solved in 200 mL water) the following morning.24 In
patients arriving at the CCU between 21:00 and 23:59,
the OGTT was performed the second morning after
admission. During the OGTT in the CCU all patients
had already taken at least one to maximally four tablets
of study medication. All patients received standard medi-
cation according to current guidelines, received counsel-
ing on diet, smoking, and lifestyle and were offered a
cardiac rehabilitation programme.1 25 Patients who were
diagnosed with new-onset diabetes were seen by an
endocrinologist.
Patients visited the outpatient clinic 2 weeks, 7 weeks,
and 4 months after discharge. At 4 months, a standar-
dized OGTT was performed after an overnight fast of at
least 8 h. In order to assess whether the study medica-
tion actually affected underlying dysglycemia rather than
masking its presence, the OGTT was scheduled at least
3 days after stopping the study medication.
End points and definitions
Primary outcomes in this prespeciﬁed analysis from the
GIPS-III trial were levels of, and change in HbA1c,
fasting glucose, postchallenge glucose, insulin levels,
cholesterol levels, body weight, BMI, and blood pressure
at 4 months, adjusting for baseline levels.
Analysis of glucose, hemoglobin, creatinine, and total
cholesterol, LDL-cholesterol, high-density lipoprotein
(HDL) cholesterol was performed as part of standard
care on standard laboratory assays (Roche Modular,
Roche Mannheim, Germany). HbA1c was measured
using an immunochemical assay (Tosoh G8, Tosoh
Bioscience Inc, South San Francisco, USA). Insulin
levels were determined post hoc from blood samples
stored at −80°C on a chemoluminescence immunoassay
2 BMJ Open Diabetes Research and Care 2015;3:e000090. doi:10.1136/bmjdrc-2015-000090
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(Architect i2000 SR Immunoassay analyzer, Abbott
Diagnostics, Abbott Park Illinois, USA). Blood samples,
other than speciﬁc glucose samples for assessment of
fasting glucose, were non-fasting samples.
An independent end point adjudication committee,
blinded to treatment allocation, using data on HbA1c
levels, OGTT, and use of medication assessed diabetic
state. Diabetes was deﬁned as an HbA1c of ≥6.5%
(48 mmol/mol), and/or a fasting blood glucose of
≥7.0 mmol/L and/or a 2 h postchallenge blood glucose
concentration of ≥11.1 mmol/L; prediabetes as an
HbA1c between 5.7% (39 mmol/mol) and 6.4%
(47 mmol/mol), and/or a fasting blood glucose of 5.6–
6.9 mmol/L, and/or a 120 min postchallenge blood
glucose 7.8–11.0 mmol/L; patients not meeting any of
these criteria were classiﬁed as normoglycemic.24
Statistical analyses
Continuous variables are reported as means±SD or
medians (IQR) for normally and non-normally distribu-
ted data, respectively. Differences between groups were
tested using Student t test or analysis of variance for nor-
mally distributed data, and Wilcoxon or Kruskall-Wallis
tests for non-normally distributed data. Differences in
proportions were assessed using χ2 tests. Analysis of
covariance was used to evaluate differences in continu-
ous variables at 4 months, adjusting for baseline values,
reported as mean with 95% CIs. Multivariable linear
regression was used to investigate associations between
continuous variables and treatment, and to adjust for
potential confounders.
Linear mixed-effects models were used to evaluate the
trajectories of variables over time. These models included
time and an interaction with study treatment as ﬁxed
effects (population-level estimates) and allowed for
participant-speciﬁc variation in baseline levels and
changes (a so-called random slope, random intercept
model). Linear, cubic, and quadratic time transformations
were considered; best ﬁt for the ﬁxed effects structure was
selected based on akaike criterion information (AIC) and
bayesian criterion information (BIC) (measures for model
ﬁt; lower is better), while the best random effects structure
was evaluated via likelihood ratio tests in nested models.
The interaction between treatment and time indicates
whether a different trajectory (slope) exists between the
two treatment groups. All reported p values are two-sided,
and a p value of <0.05 was considered signiﬁcant. All ana-
lyses were performed using R: A Language and
Environment for Statistical Computing, V.3.02 (R
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
At baseline, HbA1c measurements were available in all
but 6 (1.6%) patients. Of these 373 patients, 27 (7.2%)
had an HbA1c of ≥6.5% (48 mmol/mol; 12 in the
placebo group and 15 in the metformin group) and
excluded for the current analysis, resulting in 346
patients without diabetes.
The baseline characteristics of the patients for both
groups (metformin group, n=172; placebo group,
n=174) are presented in table 1. Both groups were com-
parable at baseline regarding age, sex, cardiovascular
risk proﬁle, cardiovascular history, physical diagnostic
measurements, and baseline markers reﬂective of renal
function, glycometabolism, and cholesterol proﬁle.
HbA1c concentration
At 4 months, HbA1c levels in the metformin group were
slightly lower than in the placebo group, adjusting for
baseline values (table 2). The mean absolute change in
HbA1c concentration from baseline to 4 months was 0.06
(95% CI 0.03 to 0.10%); 0.66 mmol/mol (95% CI 0.33 to
1.09) in the metformin group and 0.12% (95% CI 0.08%
to 0.15%); 1.31 mmol/mol (95% CI 0.87 to 1.64) in the
placebo group (p=0.049; ﬁgure 1A). Figure 2 shows the
change in HbA1c levels over time in both groups, ﬁtted
using a smoothed spline. A linear mixed-effects model
evaluating change in HbA1c over time showed a signiﬁ-
cant interaction between time and study treatment
(p=0.031), indicating different trajectories between the
metformin and placebo group (ﬁgure 2).
Fasting glucose and postchallenge glucose
All patients underwent an OGTT during hospitalization
whereas 28 patients (7.5%) refused an OGTT at
4 months (10 patients (5.7%) in the metformin group
and 18 patients (10.5%) in the placebo group).
During hospitalization for STEMI, the metformin and
placebo group had similar fasting glucose levels (6.4±1.0
vs 6.4±0.9 mmol/L, p=0.75), whereas the 120 min post-
challenge glucose levels were lower in the metformin
group compared with placebo (10.0±2.7 vs 10.6
±2.5 mmol/L; p=0.03; ﬁgure 3A). Four months after
STEMI and after stopping the study medication for at
least 5 days, there were no differences between the met-
formin and placebo group concerning the fasting
glucose levels (5.6±0.6 vs 5.6±0.7 mmol/L, p=0.76) and
the 120 min postchallenge glucose levels (7.7±2.2 vs 7.8
±2.2 mmol/L, p=0.83; ﬁgure 3B).
Insulin levels
Twenty-four hours after PCI, the non-fasting insulin level
in the metformin group was 34.5 mU/L (95% CI 29.3 to
39.6) and 33.2 mU/L (28.4 to 38.1) in the placebo group
(p=0.274). The mean absolute change in insulin levels
from baseline to 24 h was 9.2 mU/L (95% CI 4.0 to 14.3)
in the metformin group and 7.9 mU/L (95% CI 3.1 to
12.8) in the placebo group (p=0.914). Also at 4 months,
insulin levels in the metformin group did not differ from
the placebo group, adjusting for baseline values (table 2).
The mean absolute change in insulin levels from baseline
to 4 months was −3.3 mU/L (95% CI −8.64 to 2.0) in the
metformin group and −7.5 mU/L (95% CI −12.6 to
−2.4) in the placebo group (p=0.979; ﬁgure 1B).
BMJ Open Diabetes Research and Care 2015;3:e000090. doi:10.1136/bmjdrc-2015-000090 3
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Incidence of diabetes and prediabetes
New-onset diabetes, diagnosed at 4 months, was diag-
nosed in 20 patients (12%) in the metformin group and
18 patients (10%) in the placebo group (p=0.70).
Prediabetes was diagnosed in the metformin group in
108 patients (63%) and in 123 patients (71%) in the
placebo group (p=0.40) after 4 months.
Body weight and BMI
Four months after STEMI, body weight and subse-
quently BMI were lower in the metformin group com-
pared with placebo (table 2). The patients in the
metformin group did not gain weight (0.0 kg (95% CI
−0.84 to 0.90), whereas the weight gain in the control
group was 1.4 kg (95% CI 0.56 to 2.3; p=0.024; ﬁgure
1C). As a consequence, the BMI at 4 months was lower
in the metformin group than in the placebo group
(table 2). Another important factor possibly inﬂuencing
body weight is cessation of smoking. The number of
smokers at baseline did not differ between groups (table
1). At 4 months, there was no between-group difference
in cessation of smoking: 52 patients in the metformin
group had quit smoking versus 63 patients in the
placebo group (p=0.39).
Total, LDL, and HDL cholesterol
The adjusted total cholesterol levels and LDL choles-
terol levels in the metformin group were lower than the
placebo group after 4 months (table 2). The mean
reduction from baseline to 4 months in total cholesterol
in the metformin group was 1.58 mmol/L (95% CI 1.45
to 1.70) and in the placebo group 1.40 mmol/L (95%
CI 1.29 to 1.52; p=0.045; ﬁgure 1D), whereas the mean
reduction in LDL-cholesterol was 1.74 mmol/L (95% CI
1.64 to 1.84) in the metformin group and 1.54 mmol/L
(95% CI 1.44 to 1.64) in the placebo group (p=0.007;
ﬁgure 1E). The adjusted HDL-cholesterol level did not
differ among groups. The mean increase in
HDL-cholesterol from baseline to 4 months was
0.04 mmol/L (95% CI 0.01 to 0.07) in the metformin
group and 0.07 mmol/L/L (95% CI 0.04 to 0.10) in the
placebo group (p=0.153; ﬁgure 1F). At baseline, only
two patients in the metformin group and three patients
in the placebo group had a LDL-cholesterol level of
<1.9 mmol/L/L, which is the targeted level for
Table 1 Baseline characteristics
Variable Total (n=346) Metformin (n=172) Control (n=174) p Value
Age, mean (SD), years 58.1±11.7 58.1±11.9 58.2±11.6 0.968
Female sex, N (%) 87 (25) 40 (23) 47 (27) 0.496
Race or ethnic group, N (%) 0.567
Caucasian 335 (97) 168 (98) 167 (96)
Asian 7 (2.0) 3 (1.7) 4 (2.3)
Black 4 (1.2) 1 (0.6) 3 (1.7)
Cardiovascular risk factors, N (%)
Hypertension 97 (28) 50 (29) 47 (27) 0.759
Dyslipidemia 220 (64) 103 (60) 117 (67) 0.190
Current smoking 190 (55) 96 (56) 94 (54) 0.821
Positive family history 118 (34) 55 (32) 63 (36.2) 0.474
Cardiovascular history
Stroke 2 (0.6) 1 (0.6) 1 (0.6) 1.000
Previous PCI 4 (1) 1 (0.6) 3 (1.7) 0.623
Physical diagnostics at hospital admission
Body weight, mean (SD), kg 83.5±14.0 83.6±13.9 83.3±14.1 0.847
Body mass index, mean (SD), kg/m2 26.7±3.7 26.5±3.5 26.9±3.9 0.401
Systolic blood pressure, mean (SD), mm Hg 134±23 134±22 133±24 0.797
Diastolic blood pressure, mean (SD), mm Hg 84±14 84±14 84±15 0.733
Laboratory values at admission
Hemoglobin (IQR), mmol/L 8.9±0.8 8.9±0.8 8.9±0.8 0.673
Creatinine (IQR), µmol/L 72 (62–82) 72 (62–84) 73 (63–81) 0.673
Estimated GFR (IQR), mL/min/173 m2 93±21 93±23 93±19 0.947
Glucose, median (IQR), mmol/L 8.1 (7.0–9.4) 8.1 (7.0–9.2) 8.1 (7.0–9.6) 0.627
HbA1c, median (IQR), % 5.8 (5.6–6.0) 5.7 (5.6–6.0) 5.8 (5.6–6.0) 0.849
HbA1c, median (IQR), mmol/mol 40 (38–42) 39 (38–42) 40 (38–42) 0.849
Insulin, median (IQR), mmol/L 16.9 (9.8–29.2) 18.5 (10.8–30.1) 15.9 (9.3–27.8) 0.169
Total cholesterol (IQR), mmol/L 5.3 (4.8–6.0) 5.3 (4.7–6.1) 5.3 (4.8–6.0) 0.938
LDL-cholesterol (IQR), mmol/L 3.8 (3.2–4.4) 3.7 (3.1–4.5) 3.8 (3.3–4.4) 0.740
HDL-cholesterol (IQR), mmol/L 1.1 (0.9–1.3) 1.1 (0.9–1.3) 1.1 (0.9–1.3) 0.821
GFR, glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PCI, percutaneous
coronary intervention.
4 BMJ Open Diabetes Research and Care 2015;3:e000090. doi:10.1136/bmjdrc-2015-000090
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cholesterol-lowering therapy.1 Despite overall lowering
LDL values, 49 patients in the metformin versus 46
patients in the placebo group reached the
LDL-cholesterol target level of <1.9 mmol/L (p=0.397)
at 4 months. The statins used, and the equipotency of
these statins did not differ between groups, since at base-
line 12 patients in the metformin group versus 13
patients in the placebo group used statins, and at
Figure 1 Change in markers of glycometabolism and cardiovascular risk profile. Absolute changes in (95% CI) the metformin
and placebo groups in glycated hemoglobin (HbA1c) concentration (A), insulin levels (B), body weight (C), total cholesterol (D),
low-density lipoprotein (LDL)-cholesterol (E), and high-density lipoprotein (HDL)-cholesterol (F) were analyzed using analysis of
covariance.
Table 2 Measurements of glycometabolic state and cardiovascular risk profile at 4 months
Variable Metformin (n=172) Control (n=174) p Value
Physical diagnostics
Body weight, mean (95% CI), kg 83.8 (83.0 to 84.7) 85.2 (84.4 to 86.1) 0.024
Body mass index, mean (95% CI), kg/m2 26.8 (26.5 to 27.0) 27.2 (27.0 to 27.5) 0.014
Systolic blood pressure, mean (95% CI), mmHg 123 (120 to 125) 125 (122 to 127) 0.241
Diastolic blood pressure, mean (95% CI), mmHg 74 (72 to 75) 74 (72 to 75) 0.649
Laboratory values
HbA1c, mean (95% CI), % 5.83 (5.79 to 5.87) 5.89 (5.85 to 5.92) 0.049
HbA1c, mean (95% CI), mmol/mol 40.2 (39.8 to 40.6) 40.9 (40.4 to 41.2) 0.049
Insulin, mean (95% CI), mU/L 22.8 (17.5 to 28.1) 18.6 (13.5 to 23.7) 0.211
Total cholesterol, mean (95% CI), mmol/L 3.85 (3.73 to 3.97) 4.02 (3.90 to 4.14) 0.045
LDL cholesterol, mean (95% CI), mmol/L 2.10 (1.99 to 2.20) 2.30 (2.20 to 2.40) 0.007
HDL cholesterol, mean (95% CI), mmol/L 1.20 (1.16 to 1.23) 1.23 (1.20 to 126) 0.153
Values were calculated using ANCOVA, adjusted for baseline variables.
ANCOVA, analysis of covariance; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
BMJ Open Diabetes Research and Care 2015;3:e000090. doi:10.1136/bmjdrc-2015-000090 5
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4 months 153 vs 157 patients used statins (p=not signiﬁ-
cant for both time points). At hospital discharge, the
statins used and equipotency did not differ (see online
supplementary appendix, tables S1 and S2).
Blood pressure
The systolic and diastolic blood pressure at 4 months was
similar in both treatment groups: 123 mm Hg (95% CI
120 to 125) and 74 mm Hg (95% CI 72 to 75) in the
metformin group, and 125 mm Hg (95% CI 122 to 127)
and 74 mm Hg (95% CI 72 to 75) in the placebo group
(p=0.241 and p=0.649, respectively). The mean decrease
in either systolic or diastolic blood pressure from base-
line to 4 months did not differ between groups (data
not shown).
DISCUSSION
The main observation of this prespeciﬁed analysis from
the GIPS-III trial is that metformin treatment in patients
with STEMI for 4 months on top of standard care leads
to a modestly improved cardiovascular risk proﬁle com-
pared with placebo in a subselection of patients without
diabetes. HbA1c levels, weight gain, total cholesterol,
and LDL-cholesterol levels were all lower in patients
receiving metformin. A reduction in the incidence of
new-onset diabetes was not observed. Furthermore, sys-
tolic and diastolic blood pressure, insulin levels, and
HDL cholesterol levels remained unchanged by metfor-
min treatment. These results imply that metformin
might be able to modestly reduce the cardiovascular risk
in patients without diabetes on top of standard care
Figure 2 Change in glycated
hemoglobin (HbA1c) over time.
Trajectories of change in HbA1c
over time (95% CI) were analyzed
using linear mixed-effects model,
showing different trajectories
between the two treatment groups
(p=0.031).
Figure 3 Oral glucose tolerance
testing during hospitalization and
at 4 months after infarction. Bar
and whisker plots demonstrating
blood glucose concentrations
during hospitalization (A) and at
4 months (B). Each plot shows
fasting blood glucose
concentration left of the dotted
line, and 120 min postchallenge
glucose concentration right of the
dotted line. The bars represent
median (p50) and IQR (p25 and
p75) and the whiskers p5 and
p95.
6 BMJ Open Diabetes Research and Care 2015;3:e000090. doi:10.1136/bmjdrc-2015-000090
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(including statin therapy). Whether these ﬁndings are
substantial and can lead to a reduction in cardiovascular
events remains to be determined.
Our results concerning HbA1c levels are comparable
with results from the recent Carotid Atherosclerosis:
MEtformin for insulin ResistAnce (CAMERA) study, that
demonstrated that 18 months of treatment with metfor-
min in patients with coronary artery disease without dia-
betes also resulted in a reduction of HbA1c levels.19 The
Diabetes Prevention Program (DPP) demonstrated that
3 years of treatment with metformin 850 mg twice daily
signiﬁcantly lowered HbA1c in comparison to placebo.13
The DPP study demonstrated that metformin treatment
at long-term follow-up resulted in a reduction in the
development of diabetes.14 In all three studies (DPP,
CAMERA, and the GIPS-III), the observed effect of met-
formin treatment on HbA1c was signiﬁcant yet small.
The use of markers of HbA1c as a prognostic marker is
not unequivocal.25 However, the incremental prognostic
value of HbA1c on top of standard risk factors has been
established.26 Therefore, it is generally accepted that
lowering HbA1c likely is associated with improved prog-
nosis. Still, the clinical relevance of metformin-induced
lowering of HbA1c on the incidence and risk of future
major cardiac events remains to be determined.
During hospitalization, one to maximally four dosages
of metformin treatment already resulted in a lower post-
challenge blood glucose concentrations compared with
placebo. Since we did not measure fasting insulin levels
24 h after PCI, this effect could be due to directly lower-
ing insulin resistance, but also due to other glucose-
lowering effects of metformin, such as reduction of
hepatic gluconeogenesis may be of effect.
Hyperglycemia is often present during and the days fol-
lowing myocardial infarction, and is associated with
impaired myocardial reperfusion, larger myocardial
infarct size, and impaired outcome.3 Therefore, many
studies using insulin-based strategies have aimed at low-
ering glucose levels during myocardial infarction.27–29
However, none of those trials showed improved
outcome, yet all of those trials concluded that lowering
insulin resistance was achieved and associated with
improved outcome. Regrettably, the insulin-based ther-
apies instituted increased risk of hypoglycemia and mor-
tality, resulting in an overall adverse effect. Our analysis
suggests that metformin can lower glucose levels during
STEMI, without the adverse effects of insulin-based low-
ering strategies. Whether administration of metformin
prior to reperfusion, with adequate blood levels of met-
formin, in patients with STEMI (for instance in the
ambulance) will result in improved outcome, cannot be
deducted from this trial.
Another very interesting and important observation in
our study was that metformin prevented weight gain. The
overall weight gain after STEMI (in GIPS-III this was 1.4 kg
in the placebo group) is likely due to inactivity after myo-
cardial infarction. There was no difference in the number
of patients who stopped smoking after STEMI between
both groups, suggesting that cessation of smoking did not
affect these results. The DPP study group calculated that
64% of the effect of metformin treatment on cardiovascu-
lar risk reduction was caused by weight reduction.30
Fontbonne et al20 demonstrated in The BIGuanides and
Prevention of Risks in Obesity (BIGPRO1) study that met-
formin treatment (850 mg twice daily) for 1 year resulted
a weight reduction of 1.2 kg compared with placebo. In
support of this, Preiss et al19 demonstrated in the CAMERA
study that metformin treatment for 18 months resulted in
a mean weight loss of 3.2 kg compared with placebo. So, if
weight reduction is one of the targets for improvement of
cardiovascular risk, metformin should be considered as an
addendum to achieve this.
Our study demonstrated that metformin effectively
lowers LDL cholesterol and total cholesterol levels on
top of initiation of statin therapy. The BIGPRO1 study
showed that metformin treatment for 1 year resulted in
a reduction of 0.16 mmol/L in total cholesterol and
0.12 mmol/L in LDL-cholesterol.20 However, these
patients were not treated with statins or other
lipid-lowering drugs. In contrast, Preiss et al19 did not
report an effect of 18 months of metformin treatment
on cholesterol levels in patients without diabetes with
coronary artery disease in the CAMERA study. One of
the eligibility criteria in the CAMERA study was statin
therapy, which all patients received already for 6.5 years
on average. In our study, only 25 of 346 (7.2%) of
patients used statins since the STEMI mostly was their
ﬁrst presentation with cardiovascular disease, but at hos-
pital discharge 99.5% of patients in our study received
statins.22 Second, the total cholesterol levels at baseline
in the CAMERA were much lower than in our trial (4.3
vs 5.3 mmol/L). Third, the average reduction in choles-
terol level at 6 months was 0.03 mmol/L in the
CAMERA trial, whereas in our trial on average a reduc-
tion of 1.4 mmol/L was observed, with a larger reduc-
tion in the metformin group compared with the placebo
group. Since the effect of metformin lowering total chol-
esterol and LDL on top of statin therapy was clearly
visible in our study, metformin may exert cholesterol-
lowering qualities during initiation of treatment.
This prespeciﬁed substudy of the GIPS-III trial had
several strengths. The GIPS-III had a double-blind,
placebo-controlled trial, and included patients at the
same time point in their illness, namely directly after
PCI for STEMI. All end points were adjudicated by an
independent end point committee. The dosages of met-
formin used (500 mg bid) are commonly used to treat
type 2 diabetes mellitus. A potential weakness of the
GIPS-III trial was that it was not designed for mortality
reduction trough secondary prevention of the cardiovas-
cular risk proﬁle. However, several clinically relevant and
targeted markers were lowered by metformin therapy,
suggesting the sample size is sufﬁcient to address cardio-
vascular risk proﬁle. The study medication was only
administered for 4 months, which in terms of secondary
prevention is short.
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Altogether, we observed that metformin treatment in
patients without diabetes presenting with STEMI,
resulted in prevention of gain in body weight, improved
levels of HbA1c, and improved levels of LDL and total
cholesterol. Estimating the total effect size on cardiovas-
cular risk of these combined effects is difﬁcult. A risk
calculator for outcome after STEMI, integrating all
important known variables, has yet to be developed.
However, quantiﬁcation of the effect sizes on outcome is
necessary in order to establish the usefulness and
beneﬁt of metformin in secondary prevention.
Therefore, further study on the effects of metformin on
cardiovascular risk proﬁle and prognosis in patients with
STEMI are warranted. Currently, the Glucose Lowering
in Non-diabetic hyperglycemia Trial (GLINT,
ISRCTN34875079) is an ongoing double-blind, rando-
mized controlled trial set to include over 12 000 patients
designed to assess the effect of metformin in non-
diabetic hyperglycemia on cardiovascular risk.
CONCLUSION
In patients with acute myocardial infarction at risk for
diabetes, 4 months of treatment with metformin on top
of optimal treatment resulted in a modestly more favor-
able cardiovascular risk proﬁle compared with placebo.
Metformin treatment improved glycemic control and
cholesterol levels, and prevented gain in body weight.
Whether these favorable effects on risk factors can be
translated to improved long-term outcomes requires
further study.
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